Orciprenaline is used to treat asthma, chronic bronchitis, emphysema and bronchospasm.
What is Orciprenaline?
Orciprenaline is an agonist of beta-2 adrenergic receptors. It works by stimulating the receptors of the smooth muscle and by stimulating the synthesis of the cyclic AMP molecules through activation of the enzyme adenylate cyclase. The final effect is a bronchodilator.
How should Orciprenaline be taken?
Orciprenaline should be taken orally, usually in the form of syrup.
Side effects associated with Orciprenaline
Possible side effects of Orciprenaline include the following:
- Dizziness
- Headache
- Nervousness
- Sweating
- Tremors
- Sleep disorders
It is important to contact a doctor immediately if taking Orciprenaline triggers:
- Chest pains
- Convulsions
- Urticaria
- Fast or irregular heartbeat
- Increased blood pressure
- Psychological disorders
- Nausea or vomiting
- Difficulty urinating
- Muscle aches
- Muscle cramps
- Unusual tiredness or weakness
The intake of the drug should be discontinued immediately in the event of:
- Hoarseness
- Swollen eyelids , face, genitals, hands or feet, lips , throat or tongue
- Sudden difficulty breathing or swallowing
- Tightness in the throat
Contraindications and warnings associated with the use of Orciprenaline
Taking Orciprenaline is contraindicated in pregnancy.
Before taking the drug, it is important to inform your doctor:
- If you have any allergies to the active substance or any other medication
- If you are taking any other medications, herbal remedies or supplements. Mentioning in particular anticholinergics, beta-blockers, MAO inhibitors, sympathomimetics, theophylline and tricyclic antidepressants
- If you suffer (or have suffered) from asthma or emphysema associated with high blood pressure, coronary heart disease, congestive heart failure, diabetes, glaucoma or hyperthyroidism
- If you had recently suffered a heart attack
- If you are pregnant or breastfeeding
It is also important to inform surgeons and dentists of any ongoing treatment with Orciprenaline.